Whilst biologic based approaches to target CTSS have been substantially less investigated, encouraging findings have been generated, as exemplified by the monoclonal antibody Fsn0503, which was capable of attenuating invasion and angiogenesis within colorectal tumour models (Burden et al., 2009; Ward et al., 2010). Here, CTSS is linked to colorectal neoplasm.